These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 27025857

  • 1. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S, Unterberg A, von Deimling A, Debus J.
    J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
    [Abstract] [Full Text] [Related]

  • 2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [Abstract] [Full Text] [Related]

  • 3. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
    Minniti G, Scaringi C, Arcella A, Lanzetta G, Di Stefano D, Scarpino S, Bozzao A, Pace A, Villani V, Salvati M, Esposito V, Giangaspero F, Enrici RM.
    J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
    Yang P, Zhang W, Wang Y, Peng X, Chen B, Qiu X, Li G, Li S, Wu C, Yao K, Li W, Yan W, Li J, You Y, Chen CC, Jiang T.
    Oncotarget; 2015 Dec 01; 6(38):40896-906. PubMed ID: 26503470
    [Abstract] [Full Text] [Related]

  • 6. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):661-7. PubMed ID: 22414280
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Matschke J, Roth P, Suresh MP, Kamp MA, Rushing EJ, Pietsch T, von Deimling A, Sabel M, Loeffler M, Weller M, Reifenberger G.
    Eur J Cancer; 2021 Apr 01; 147():84-94. PubMed ID: 33631540
    [Abstract] [Full Text] [Related]

  • 9. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V, Scarpino S, Maurizi Enrici R, Giangaspero F.
    J Neurooncol; 2011 Apr 01; 102(2):311-6. PubMed ID: 20686820
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A.
    Neuro Oncol; 2017 Mar 01; 19(3):394-404. PubMed ID: 27571882
    [Abstract] [Full Text] [Related]

  • 12. Clinicopathologic and genomic features of gliosarcomas.
    Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH.
    J Neurooncol; 2012 May 01; 107(3):643-50. PubMed ID: 22270848
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
    Kavouridis VK, Ligon KL, Wen PY, Iorgulescu JB.
    J Neurooncol; 2022 May 01; 158(1):111-116. PubMed ID: 35474499
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M, Goeppert M, Felsberg J, Steiger HJ, Sabel M.
    Br J Neurosurg; 2013 Aug 01; 27(4):430-5. PubMed ID: 23418781
    [Abstract] [Full Text] [Related]

  • 18. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W, DIRECTOR Study Group.
    Clin Cancer Res; 2015 May 01; 21(9):2057-64. PubMed ID: 25655102
    [Abstract] [Full Text] [Related]

  • 19. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
    Thon N, Thorsteinsdottir J, Eigenbrod S, Schüller U, Lutz J, Kreth S, Belka C, Tonn JC, Niyazi M, Kreth FW.
    J Neurol; 2017 Feb 01; 264(2):350-358. PubMed ID: 27921166
    [Abstract] [Full Text] [Related]

  • 20. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.
    Pediatr Blood Cancer; 2007 Apr 01; 48(4):403-7. PubMed ID: 16609952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.